• home
  • articles
  • authors
  • Reviewers
  • About the Journal
  • About the Journal
  • About the Journal
  • About the Journal
  • e-Submission

Indexed/Covered by

J Vet Sci 2018; 19(5): 600-607  https://doi.org/10.4142/jvs.2018.19.5.600
Pharmacokinetics of enrofloxacin HCl-2H2O (Enro-C) in dogs and pharmacokinetic/pharmacodynamic Monte Carlo simulations against Leptospira spp.
Hector Sumano1, Luis Ocampo1, Graciela Tapia2, Corazon de Jesus Mendoza1, Lilia Gutierrez1,*
Departments of 1Physiology and Pharmacology, and 2Genetics and Biostatistics, National Autonomous University of Mexico (UNAM), Mexico City 04510, Mexico
Correspondence to: Tel: +52-55-56-22-59-80; Fax: +52-55-56-22-59-08; E-mail: liliago@unam.mx
Received: January 17, 2018; Revised: February 24, 2018; Accepted: March 20, 2018; Published online: September 30, 2018.
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) ratios of reference enrofloxacin (Enro-R) and enrofloxacin as HCl-2H2O (Enro-C), as well as Monte Carlo simulations based on composite MIC50 and MIC90 (MIC, minimum inhibitory concentration) vs. Leptospira spp., were carried out in dogs after their intramuscular (IM) or oral administration (10 mg/kg). Plasma determination of enrofloxacin was achieved by means of high-performance liquid chromatography. Maximum plasma concentration values after oral administration were 1.47 ± 0.19 μg/mL and 5.3 ± 0.84 μg/mL for Enro-R and Enro-C, respectively, and 1.6 ± 0.12 μg/mL and 7.6 ± 0.93 μg/mL, respectively, after IM administration. Areas under the plasma vs. time concentration curve in 24 h (AUC0–24) were 8.02 μg/mL/h and 36.2 μg/mL/h for Enro-Roral and Enro-Coral, respectively, and 8.55 ± 0.85 μg/mL/h and 56.4 ± 6.21 μg/mL/h after IM administration of Enro-R and Enro-C, respectively. The PK/PD ratios and Monte Carlo simulations obtained with Enro-C, not Enro-R, indicated that its IM administration to dogs will result in therapeutic concentrations appropriate for treating leptospirosis. This is the first time enrofloxacin has been recommended to treat this disease in dogs.
Keywords: dogs, enrofloxacin, leptospirosis, pharmacodynamics, pharmacokinetics


© 2018 The Korean Society of Veterinary Science.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.